$ZydaClin^{TM}\\$

(clindamycin)

Oral Drops

liquid

For Use in Dogs & Cats

Equivalent to 25 mg per mL clindamycin

Not for use in humans

Keep out of reach of children

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

ANADA 200-538, Approved by FDA

DESCRIPTION

ZydaClinTM Oral Drops contain clindamycin hydrochloride which is the hydrate salt of clindamycin. Clindamycin is a semisynthetic antibiotic produced by a 7(S)-chlorosubstitution of the 7(R)-hydroxly group of a naturally produced antibiotic produced by *Streptomyces lincolnensis var. lincolnensis*.

ZydaClin™ Oral Drops (For Use in Dogs and Cats) is a palatable formulation intended for oral administration. Each mL of ZydaClin™ Oral Drops liquid contains clindamycin hydrochloride equivalent to 25 mg clindamycin; and ethyl alcohol, 8.64%.

ACTION

Site and Mode of Action: Clindamycin is an inhibitor of protein synthesis in the bacterial cell. The site of binding appears to be in the 50S sub-unit of the ribosome. Binding occurs to the soluble RNA fraction of certain ribosomes, thereby inhibiting the binding of amino acids to those ribosomes. Clindamycin differs from cell wall inhibitors in that it causes irreversible modification of the protein-synthesizing subcellular elements at the ribosomal level.

MICROBIOLOGY

Clindamycin is a lincosaminide antimicrobial agent with activity against the wide variety of aerobic and anaerobic bacterial pathogens. Clindamycin is a bacteriostatic compound that inhibits bacterial protein synthesis by binding to 50S ribosomal sub-unit. The minimum inhibitor concentrations (MICs) of Gram-positive and obligate anaerobic pathogens isolated from dogs and cats in the United States are presented in the Table 1 and Table 2. Bacteria were isolated in 1998-1999. All MICs were performed in accordance with the National committee for Clinical Standards (NCCLS).

Table 1. Clindamycin MIC Values (µg/mL) from Diagnostic Laboratory Survey Data Evaluating Canine Pathogens in the U.S. during 1998-99'

Organism	Number of isolates	MIC _{so}	MICes	MIC _{so}	Range
Soft Tissue/Wound	•		15 (8//-		
Staphylococcus aureus	17	0.5	0.5	≥4.0	0.25-≥4.0
Staphylococcus intermedius	28	0.25	0.5	≥4.0	0.125-≥4.0
Staphylococcus spp.	18	0.5	0.5	≥4.0	0.25-≥4.0
Beta-hemolytic streptococci	46	0.5	0.5	≥4.0	0.25-≥4.0
Streptococcus spp.	11	0.5	≥4.0	≥4.0	0.25-≥4.0
Osteomyelitis/Bone	2			ir-	
Staphylococcus aureus	20	0.5	0.5	0.5	0.5
Staphylococcus Intermedius	15	0.5	≥4.0	≥4.0	0.25-≥4.0
Staphylococcus spp.	18	0.5	≥4.0	≥4.0	0.25-≥4.0
Beta-hemolytic streptococci	21	0.5	2.0	2.0	0.25-≥4.0
Streptococcus spp.	21	≥4.0	≥4.0	≥4.0	0.25-≥4.0
Dermal/Skin ^a					- Section
Staphylococcus aureus	25	0.5	≥4.0	≥4.0	0.25-≥4.0
Staphylococcus intermedius	48	0.5	≥4.0	≥4.0	0.125-≥4.0
Staphylococcus spp.	32	0.5	≥4.0	≥4.0	0.25-≥4.0
Beta-hemolytic streptococci	17	0.5	0.5	0.5	0.25-0.5

¹ The correlation between the in vitro susceptibility data and clinical

Table 2. Clindamycin MIC Values (µg/mL) from Diagnostic Laboratory Survey Data Evaluating Feline Pathogens from Wound and Abscess Samples in the U.S. during 1998'

Organism	Number of Isolates	MIC.	MIC ₉₀	Range
Becteroides/ Prevotella	30	0.06	4.0	≤0.015-4.0
Fusobacterium spp.	17	0.25	0.25	≤0.015-0.5
Peptostreptococcus spp.	18	0.13	0.5	≤0.015-8.0
Porphyromonas spp.	13	0.06	0.25	≤0.015-8.0

¹ The correlation between the in vitro susceptibility data and clinical response

PHARMACOLOGY

Absorption: Clindamycin hydrochloride is rapidly absorbed from the canine and feline gastrointestinal tract.

response has not been determined.

2 Soft Tissue/Wound: includes samples labeled wound, abscess, aspirate, exudates, draining tract, lesion, and mass.


³ Osteomyelitis/Bone: includes samples labeled bone, fracture, joint, tendon.

⁴No range, all isolates yielded the same value.

⁵ Dermal/Skin: includes samples labeled skin, skin swab, biopsy, incision,


Dog Serum Levels:

Serum levels at or above $0.5 \mu g/mL$ can be maintained by oral dosing at a rate of 2.5 mg/lb of clindamycin hydrochloride every 12 hours. This same study revealed that average peak serum concentrations of clindamycin occur 1 hour and 15 minutes after oral dosing. The elimination half-life for clindamycin in dog serum was approximately 5 hours. There was no bioactivity accumulation after a regimen of multiple oral doses in healthy dogs.



Cat Serum Levels:

Serum levels at or above $0.5 \mu g/mL$ can be maintained by oral dosing at a rate of 5 mg/lb of clindamycin hydrochloride liquid every 24 hours. The average peak serum concentration of clindamycin occurs approximately 1 hour after oral dosing. The elimination half-life of clindamycin in feline serum is approximately 7.5 hours. In healthy cats, minimal accumulation occurs after multiple oral doses of clindamycin hydrochloride, and steady-state should be achieved by the third dose.



METABOLISM AND EXCRETION

Extensive studies of the metabolism and excretion of clindamycin hydrochloride administered orally in animals and humans have shown that unchanged drug and bioactive and bioinactive metabolites are excreted in urine and feces. Almost all of the bioactivity detected is serum after clindamycin hydrochloride product administration is due to the parent molecule (clindamycin). Urine bioactivity, however, reflects a mixture of clindamycin and active metabolites, especially N-dimethyl clindamycin and clindamycin sulfoxide.

ANIMAL SAFETY SUMMARY

Rat and Dog Data: One year Oral toxicity studies in rats and dogs at doses of 30, 100 and 300 mg/kg/day (13.6, 45.5 and 136.4 mg/lb/day) have shown clindamycin hydrochloride to be well tolerated. Differences did not occur in the parameters evaluated to assess toxicity when comparing groups of treated animals with contemporary controls. Rats administered clindamycin hydrochloride at 600 mg/kg/day (272.7 mg/lb/day) for six months tolerated the drug well; however, dogs orally dosed at 600 mg/kg/day (272.7 mg/lb/day) vomited, had anorexia and subsequently lost weight. At necropsy these dogs had erosive gastritis and focal areas of necrosis of the mucosa of the gall bladder.

Safety in gestating bitches or breeding males has not been established.

Cat Data: The recommended daily therapeutic dose range for Clindamycin Hydrochloride Oral Liquid is 11 to 33 mg/kg/day (5 to 15 mg/lb/day) depending on the severity of the condition. Clindamycin hydrochloride liquid was tolerated with little evidence of toxicity in domestic shorthair cats when administered orally at 10 X the minimum recommended therapeutic daily dose (11 mg/kg 5 mg/lb) for 15 days, and at doses up to 5 X the minimum recommended therapeutic dose for 42 days. Gastrointestinal tract upset (soft feces to diarrhea) occurred in control and treated cats with emesis occurring at doses 3 X or greater than the minimum recommended therapeutic dose (11 mg/kg/day; 5 mg/lb/day). Lymphocytic inflammation of the gallbladder was noted in a greater number of treated cats at the 110 mg/kg/day (50 mg/lb/day) dose level than control cats. No other effects were noted. Safety in gestating queens or breeding male cats has not been established.

INDICATIONS

ZydaClinTM Oral Drops (for use in dogs and cats) are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below:

Dogs: Skin infections (wounds and abscesses) due to coagulase positive staphylococci (Staphylococcus aureus or Staphylococcus intermedius). **Deep wounds and abscesses** due to Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens.

Dental infections due to *Staphylococcus aureus*, *Bacteroides fragilis*, *Prevotella melaninogenicus*, *Fusobacterium necrophorum* and *Clostridium perfringens*. **Osteomyelitis** due to *Staphylococcus aureus*, *Bacteroides fragilis*, *Prevotella melaninogenicus*, *Fusobacterium necrophorum* and *Clostridium perfringens*.

Cats: Skin infections (wounds and abscesses) due to Staphylococcus aureus, Staphylococcus intermedius, Streptococcus spp. Deep wounds and abscesses due to Clostridium perfringens and Bacteroides fragilis.

Dental infections due to *Staphylococcus aureus*, *Staphylococcus intermedius*, *Streptococcus spp.*, *Clostridium perfringens* and *Bacteroides fragilis*.

CONTRAINDICATIONS

ZydaClinTM Oral Drops are contraindicated in animals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.

Because of potential adverse gastrointestinal effects, do not administer to rabbits, hamsters, guinea pigs, horses, chinchillas or ruminating animals

HUMAN WARNINGS

Keep out of reach of children. Not for human use.

PRECAUTIONS

During prolonged therapy of one month or greater, periodic liver and kidney function tests and blood counts should be performed.

The use of ZydaClinTM Oral Drops occasionally results in overgrowth of non-susceptible organisms such as clostridia and yeasts. Therefore, the administration of ZydaClinTM Oral Drops should be avoided in those species sensitive to the gastrointestinal effects of clindamycin (see **CONTRAINDICATIONS**). Should superinfections occur, appropriate measures should be taken as indicated by the clinical situation.

Patients with very severe renal disease and/or very severe hepatic disease accompanied by severe metabolic aberrations should be dosed with caution, and serum clindamycin levels monitored during high dose therapy.

Clindamycin hydrochloride has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, ZydaClinTM Oral Drops should be used with caution in animals receiving such agents.

Safety in gestating bitches and queens or breeding male dogs and cats has not been established.

ADVERSE REACTIONS

Side effects occasionally observed in either clinical trials or during clinical use were vomiting and diarrhea.

To report a suspected adverse reaction or to request a Safety Data Sheet (MSDS) call 1-800-524-6332.

DOSAGE AND ADMINISTRATION

Dogs:

Infected Wounds, Abscesses and Dental Infections

Oral: 2.5-15.0 mg/lb body weight every 12 hours.

Duration: Treatment with ZydaClinTM Oral Drops may be continued up to a maximum of 28 days if clinical judgment indicates. Treatment of acute infections should not be continued for more that three or four days if no response to therapy is seen.

Dosage Schedule:

ZydaClin™ Oral Drops, administer 1-6 mL/10 lb body weight every 12 hours.

Dogs:

Osteomyelitis

Oral: 5.0-15.0 mg/lb body weight every 12 hours.

Duration: Treatment with ZydaClinTM Oral Drops is recommended for a minimum of 28 days. Treatment should not be continued for longer the 28 days if no response to therapy is seen.

Dosage Schedule:

ZydaClin™ Oral Drops, administer 2-6 mL/10 lb body weight every 12 hours.

Cats

Infected Wounds, Abscesses and Dental Infections

Oral: 5.0-15.0 mg/lb body weight every 24 hours depending on the severity of the condition.

Duration: Treatment with ZydaClinTM Oral Drops may be continued up to a maximum for a minimum of 14 days if clinical judgment indicates. Treatment of acute infections should not be continued for more than three to four days if no clinical response to therapy is seen.

Dosage Schedule:

ZydaClinTM Oral Drops, to provide 5.0 mg/lb administer 1 mL/5 lb body weight once every 24 hours; to provide 15.0 mg/lb administer 3 mL/5 lb body weight once every 24 hours.

HOW SUPPLIED

ZydaClinTM Oral Drops is available as 20mL filled in 30 mL bottles (25 mg/mL) supplied in packers containing 12 cartoned bottles with direction labels and calibrated dosing droppers.

To report a suspected adverse reaction or to request a Safety Data Sheet (MSDS) call 1-800-524-6332.

Store at controlled room temperature 20°-25°C (68°-77°F) [see USP].



O VET ONE ZydaClin*

Oral Drops liquid FOR USE IN DOGS AND CATS

ANIMAL SAFETY SUMMARY

Rat and Dog Data: One year oral toxicity studies in rats and dogs at doses of 30, 100 and 300 mg/kg/day (13.6, 45.5 dose of 30, 100 and 300 mg/kg/day (13.6, 45.5 and 13.5 4 mg/blotdy) have shown clindamyrich hydrochloride captures to be well tolerated. Differences old not occur in the perembers evaluated to assess tracify when comparing groups of treated animals with contemporary controls. Rate animizations clindamyrich hydrochloride at 600 mg/kg/day (27.2.7 mg/fb/day) for six months tolerated the day well however, dogs only dosed at 600 mg/kg/day (27.2.7 mg/fb/day) vomited, had ancreals, and autoequirully last weight. All notopay have dogs had omerine gastrifts and focal areas of nacrosis of the musics of the gall-badder.

Safety in gestating bitches or breeding males has

Cat Data: The recommended daily therapoutic dose Cat Data: The recommended daily therapolitic cose-range for clindamycin hydrochrotic (2-ydsoCin** Oral Drope) is 11 to 35 mg/kg/sigv (5 to 15 mg/bt/sigv) depending on the severity of the condition. Clindamycin hydrochloride liquid was tolerated with tiots evidence of toxicity in domestic shorthad with tiots evidence of toxicity in domestic shorthad with severity of toxicity in the minimum. recommended therapeutic daily dose (11 mg/kg; 5 mg/b) for 15 days, and at doses up to 5x the migral for 15 days, and at occess up to 5x die minimum recommended therapeutic dose for 42 days. Gastrointastinal tract upset (soft feces to darshes) occurred in central and treated cafs with emetic occurring at doses Six or greater than the minimum recommended therapeutic dose (11 mg/kg/day; 5 mg/fb/day). Lymphocytic inflammation of the galibladder was noted in a greater number of treated cats at the 110 mg/kg/day (50 mg/fb/day) dose level than for control cats. No other effects were noted. Safety in gestating queens or breeding male cats has not been established.

O VET ONE ZydaClin*

Oral Drops liquid FOR USE IN DOGS AND CATS

INDICATIONS

"ZydaClin" Oral Drops (for use in pags and cots) are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed

Doos: Skin infections (wounds and abscesses) due to tragulase positive Staphylococci (Staphylococcus annus or Staphylococcus Informedias). Deep wounds and abscesses due to Bestevoiles Fragilis, Prevoletta metaningenicus, Fusobacteri-um necrophorum and Clostridium perforgeris.

Dental infections due to Staphylococcus auraus, Bacters fragilis, Prevatella melaninogenicus, Fusobecterium necropho-rum and Closchridium perfringens, Deteempelitiis due to Staphylo-coccus aureus, Bacteroides fragilis, Provotalla malaninogenicus, Fusobacterium necrophorum and Closchrium perfinigens.

Cats: Skin infections (wounds and abscesses) due to Staphylococcus aureus, Staphylococcus intermedius, Straphonoc-cus spp. Deep wounds and abscesses due to Closhibium perfringers and Bacteroxides fragilis.

Dental infections due to Staphylococcus aureus, Staphylococ cus intermedius, Streptococcus spp., Clostrichum perfringens and Bacteroldes fragilis.

CONTRAINDICATIONS

ZydeCtin¹⁴ Oral Crops are contraindicated in animals with a history of hypersensitivity to preparations containing clindamyon or

Securate of potential adverse gastrointestinal effects, do not administer to rabbits, hamsters, guines pigs, horses, chinchillas or ruminating animals.

Keep out of reach of children. Not for use in humans.

PRECAUTIONS

During prolonged therapy of one month or greater, periodic liver and kidney function feets and blood counts should be performed.

The use of ZydaClin^{to} Oral Crops occasionally results in overthe Use of cytosum of the coupling season in over-growth of non-exceptible organisms such as clostridia and yeasts. Therefore, the administration of ZydoChin "Oral Drops should be avoided in those species sensitive to the gastraintest-nal effects of clindamyoin (see CONTRAINDICATIONS). Should superinfections occur, appropriate measures should be taken as indicated by the clinical sibustion.

O VETONS ZydaClin* Oral Drops liquid

FOR USE IN DOGS AND CATS

Patients with very severe renal disease and/or very severe hepatic disease accompanied by sower metabolic abernations should be closed with caution, and serum clindamycin levels monitored during high-dose therapy.

mycin hydrochioride has been shown to have neuro has blocking proporties that may enhance the action of other neuromascular blocking agents. Therefore, 2ydeClar* Oral Drops should be used with caution in animals receiving such agents.

Safety in gestating bitches and queens or breeding male dogs and gats has not been established.

ADVERSE REACTIONS

Side effects occasionally observed in either clinical trials or during clinical use were vomiting and diarrhea.

report adverse reactions or a suspected adverse reaction call

DOSAGE AND ADMINISTRATION

Infected Wounds, Abscesses, and Dental Infections

Oral: 2.5-15.0 mg/lb body weight every 12 hours.

Duration: Treatment with ZydaClin® Oral Drops may be continued up to a maximum of 28 days if clinical judgment indicates. Treatment of poute infections should not be continued for more than three or four days if no response to therapy is seen.

DOSAGE SCHEDULE: ZydaClin** Oral Drops, administer 1-6 mL/10 ibs body weight every 12 hours.

Dogs: Osteomyelitis

Oral: 5.0-15.0 mg/b body weight every 12 hours.

Duration: Trestment with ZydoCin¹⁴ Oral Drops is recommended for a minimum of 28 days. Treatment should not be continued for longer than 28 days if no response to therapy is seen.

O VETONE ZydaClin* Oral Drops liquid

FOR USE IN DOGS AND CATS

DOSAGE SCHEDULE: Zyda/Clin™ Oral Drops, administer 2-6 mL/10 lbs body weight every 12 hours.

fected Wounds, Abscesses, and Dental Infections

Oral: 5.0 - 15.0 mg/lb body weight once every 24 hours depending on the severity of the condition.

Duration: Treatment with ZydaClin^{to} Oral Drops may be continued up to a maximum of 14 days if clinical judgment indicates. Treatment of scute infections should not be continued for more than three to four days if no clinical response to therapy is seen.

Dosage Schedule: ZydeClin* Oral Drops, to provide 5.0 mg/b, administer 1 mL/5 fbs body weight once every 24 hours, to provide 15.0 mg/b, administer 3 mL/5 lbs body weight once

ZydaChin^{to} Oral Drope is available as 20 mL filled in 30 mL bottles (25 mg/mL) supplied in packers containing 12 cartoned bottles with direction labels and calibrated dosing droppers.

safety data sheet (MSDS), call 1-888-524-6332.

Store at 20°C - 25°C (68°F - 77°F) [see USP].



Distributed by: MWI Boise, ID 83705 (888) 694-8381 erww.VetOne.net

Monufactured by Birneda, Inc. Le Sueur, MN 50058

8CU008 Rev. 06/13

♦ VET one ZydaClin* Oral Drops liquid

FOR USE IN DOGS AND CATS

O verone ZydaClin" Oral Drops liquid FOR USE IN DOGS AND CATS

ANADA 200-638, Approved by FDA

Caution: Federal law restricts this drug to use by or on the order of a licence veterinarian.

DISCRIPTION

2-pásilin¹⁹ Dral Drops contain clindarrycia hydrochlorida which is the hydrated ant of clindarrycia. Clindarrycia is a semisynthetic antibiotic produced by a 7(5)-chirocoptathution of the 7(8)-hydrocytesopa in contained produced antibiotic produced by Shrystonyses incolvensis and introduced.

ZydaDin" Oral Drops (For Use in Dogs and Cats) is a palabable formulation intended for oral administration. Each mi. of ZydaClin" Oral Brops liquid contains clindarrycin hydrochishide equivalent to 25 mg. clindarrycin; and ethyl alcohol, 8,64%.

ACTIONS

ACTIONS
Site and Midde of Action: Clinistrayon is an inhibitor of protein synthesis in the bacterial coll. The site of binding appears to be into 505 sain-vall of the ribosans. Binding occurs to the social service of the result of the ribosans. Binding occurs to the socials RNA fraction of certain ribosomes, thereby inhibiting the binding of annion acids to those ribosomes. Clinical demands of the ribosomes and the ribosomes of the ribosomes and ribosomes are confident on of the protein-synthesizing suboelular elements of the ribosomes limits.

MICROBIOLOGY

Clindamyoln is a tinosaminide antimicrobial agent with activity Cinctamyonis is a incommission artiviscolaria queri with activity against a wide vanisty of accords and assemble basing phrogene. Circlamyonis is a beckeledatic compound that inhibits bacterial protein ophthesis by binding in the 505 intocarnal solu-init. The minimum inhibitary concernitions (MICI) of Comm-pastive and obligate assemble performs instanted intro diega and cals in the Little States are presented in Table 1 and Table 2. Bacterial were located in 1988-1999, All MICLs were performed in accordance with the States are Commissed for Cinical Laboratory Standards (NICLES).

O VETONO ZydaClin*

Oral Drops liquid FOR USE IN DOGS AND CATS

Table 1. Clindamycin MIC Values (µg/mL) from Diagnostic Laboratory Survey Data Evaluating Canine Pathogens in the U.S. during 1998-99*

Organism	bolates	MIC	MCa	MIC	Range
Soft Tisque/Wours	d ^a	Constitution of the Consti			
Stophylococcus sureus	17	0.5	0.5	≥4.0	0.25-≥4.0
Eliptytococcus informedica	28	0.25	0.5	≥4.0	0.125-≥4.0
Strokylococcus spe	18	0.5	0.5	≥4.0	0.25-24.0
Beta-hamolytic streptococci	48	0.5	0.5	24.0	0.25-24.0
Streptonoccus Spp.	11	0.5	≥4.0	≥4.0	0.25-24.0
Osteomyelitis/Bon	e ¹				
Stephylococcus aureus	20	0,5	0.5	0.5	0.54
Staphylosoccus intervesius	15	0.5	24.0	≥4.0	0.25-24.0
Stephylococcust 809	18	0.5	24.0	≥4.0	0.25-≥4.0
Beta-nemolytic streptococci	21	0.5	2.0	2.0	0.25-24.0
Streptococcus spp.	21	≥4.0	≥4.0	≥4.0	0.25-≥4.0
Dermal/Skin ⁶					
Stephylococcus awaxa	25	0.5	24.0	≥4.0	0.25-≥4.0
Stophylococcus intermedius	48	0.5	24.0	≥40	0.125-≥4.0
Stephylococcus 669.	32	0.5	240	≥4.0	0.25-≥4.0
Bata-hemolytic streptococci	17	0.5	0.5	0.5	0.25-0.5

labeled wound, stracers, ass includes surgery, part, sesses, and mass, executes booled bons, fracture, joint,

O VET ON ZydaClin" Oral Drops liquid


FOR USE IN DOGS AND CATS

Cliedamycin MIC Values (pg/ml.) from Diagnostic forly Survey Data Evaluating Feline Pathogens from I and Abscess Samples in the U.S. during 1998

Organism	Number of lockets	MIS.,	MICM	Range
Dectyroldys/ Presidelle	30	0.06	4.0	≤0.015-4.0
Fusebacterium app.	17	0.25	0.25	≤0.015-0.5
Peptisatreplecoccus 899	18	0.13	0.5	≤0.015-8.0
Porphyroresias spp.	13	0.08	0.25	≤0.015-8.0

PHARMACOLOGY Absorption: Clindarrycin hydrochloride is rapidly absorbed from the canine and feline gastrointestinal tract.

Dog Sexom Levelo:
Serom levels of or above 0.5 johrni, can be meintained by oral doding rat on the oral 2.5 mg/h of clindamyon hydrochloride every 12 hours. This same study revealed that average pask settler constitutions of clindamyoin court line and 5 firmitiages above or doding. The skirtnington half-tils, for clindamyoin in degreement was approximately 5 focus. These was no bioactivity accumulation after a regimen of multiple oral doses in healthy rives.




O VET ON ZydaClin" Oral Drops liquid

FOR USE IN DOGS AND CATS

Cat Serum Levels:
Serum levels at or above 0.5 pg/ml, can be maintained by our disching at a rate of 5 mg/ls of chickenyon hydrochisets logid every 24 bears, a serum power serum consentation of chickenyon accurs approximately 1 hour after out discing. The elimination half-ind chickenyon in setting the approximately 1 hour after out discing. The chimination half-ind chickenyon in a perfect winterly 75 hours, in healthy colds, minimal accumulation accurs after multiple and described of clicidation in hydrochinidae, and steady-state should be achieved by the third frice.

Citedatrycin Scrum Concentrations 5 mg/lo (11 mg/kg) After Single One Toxic of Chrominals Authorities Linear to Cots



METABOLISM AND EXCRETION
Enlasses studies of the metabolism and excretion of clinicaryon hydrochrevide editionation of the committee of the committee of the committee of carrier and the committee of the committ

ZYDACLIN

clindamycin solution/ drops

Product Information

 Product Type
 PRESCRIPTION ANIMAL DRUG
 Item Code (Source)
 NDC:13985-555

Route of Administration ORAL

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength

CLINDAMYCIN HYDROCHLORIDE (UNII: T200Q1YN1W) (CLINDAMYCIN - UNII:3U02EL437C) CLINDAMYCIN 25 g in 1 mL

Packaging

# Item Code	Package Description	Marketing Start Date	Marketing End Date
1 NDC:13985-555-25	20 mL in 1 BOTTLE		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANADA	ANADA200538	07/25/2013	

Labeler - MWI (019926120)

Registrant - Bimeda Inc., Division of Cross Vetpharm Group (060492923)

Establishment

Name	Address	ID/FEI	Business Operations
Bimeda Inc., Division of Cross Vetpharm Group		060492923	manufacture

Revised: 12/2017 MWI